

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HALBERT DAVID D</u> <hr/> (Last) (First) (Middle) C/O CARIS LIFE SCIENCES, INC. 750 W. JOHN CARPENTER FREEWAY, SUITE 800 <hr/> (Street) IRVING TX 75039 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/17/2025	3. Issuer Name and Ticker or Trading Symbol <u>Caris Life Sciences, Inc. [CAI]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,023,250 ⁽¹⁾	D	
Common Stock	16,263,467	I	See Footnote ⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(3)	(3)	Common Stock	97,354,127	0	I	See Footnote ⁽²⁾⁽⁴⁾
Series B Preferred Stock	(3)	(3)	Common Stock	7,407,408	0	I	See Footnote ⁽²⁾⁽⁴⁾
Stock Option	(5)	11/14/2028	Common Stock	2,000,000	2.44	D	

1. Name and Address of Reporting Person*
HALBERT DAVID D

 (Last) (First) (Middle)
 C/O CARIS LIFE SCIENCES, INC.
 750 W. JOHN CARPENTER FREEWAY, SUITE 800

 (Street)
 IRVING TX 75039

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Caris Halbert, L.P.

 (Last) (First) (Middle)
 C/O CARIS LIFE SCIENCES, INC.
 750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)
IRVING TX 75039

(City) (State) (Zip)

1. Name and Address of Reporting Person*
ADAPT I Ltd.

(Last) (First) (Middle)
C/O CARIS LIFE SCIENCES, INC.
750 W. JOHN CARPENTER FREEWAY, SUITE
800

(Street)
IRVING TX 75039

(City) (State) (Zip)

1. Name and Address of Reporting Person*
Carisome I, L.P.

(Last) (First) (Middle)
C/O CARIS LIFE SCIENCES, INC.
750 W. JOHN CARPENTER FREEWAY, SUITE
800

(Street)
IRVING TX 75039

(City) (State) (Zip)

Explanation of Responses:

1. Includes 360,750 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.
2. The Common Stock reported herein includes (i) 5,028,802 shares of Common Stock held of record by ADAPT I Ltd., (ii) 8,414,427 shares of Common Stock held of record by Carisome I, L.P., (iii) 645,149 shares of Common Stock held of record by Caris Investment II Ltd and (iv) 2,175,089 shares of Common Stock held of record by Caris Investment III Ltd. Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.
3. Each share of preferred stock is convertible at the holder's option into 0.25 shares of Common Stock of the Issuer, subject to adjustment in accordance with the certificate of formation, and will automatically convert upon the closing of the initial public offering of the Issuer's Common Stock.
4. The preferred stock reported herein includes (i) 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd., (ii) 93,854,124 shares of Common Stock underlying Series A Preferred Stock held of record by Caris Halbert, L.P. and (iii) 7,407,408 shares of Common Stock underlying Series B Preferred Stock held of record by Caris Halbert, L.P. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.
5. The stock option is fully vested and exercisable.

Remarks:

Founder, Chairman, and Chief Executive Officer. Exhibit 24 - Power of Attorney.

David Halbert, /s/ J.
Russel Denton, Attorney-in-Fact 06/17/2025

Carisome I, L.P., /s/ J.
Russel Denton, Attorney-in-Fact 06/17/2025

ADAPT I Ltd., /s/ J.
Russel Denton, Attorney-in-Fact 06/17/2025

Carisome I, L.P., /s/ J.
Russel Denton, Attorney-in-Fact 06/17/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Caris Life Sciences, Inc. (the “Company”), the undersigned hereby constitutes and appoints the individuals named on Exhibit A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned’s true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the United States Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in- fact may approve in such attorney-in-facts discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 13th, 2025.

By: /s/ David D. Halbert

Name: David D. Halbert

Caris Halbert, L.P.

By: Caris Investment Management, LLC, its General Partner

By: /s/ David D. Halbert

Name: David D. Halbert

Title: Managing Member

ADAPT I LTD.

By: DDH Adapt Trust, its General Partner

By: /s/ David D. Halbert

Name: David D. Halbert

Title: Trustee

CARISOME I, L.P.

By: DDH Carisome Trust, its Managing General Partner

By: /s/ David D. Halbert

Name: David D. Halbert

Title: Trustee

CARIS INVESTMNT III LTD.

By: Caris Investment Management, LLC, its General Partner

By: /s/ David D. Halbert

Name: David D. Halbert

Title: Managing Member

Exhibit A

Individual Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

1. J. Russel Denton
 2. Luke Power
 3. Michael R. Sullivan
 4. Ginger L. Appleberry
-